Asymmetric dimethylarginine (ADMA) modulates endothelial function--therapeutic implications (Q44780001)

6 December 2017

Asymmetric dimethylarginine (ADMA) modulates endothelial function--therapeutic implications (English)

1 reference

6 December 2017

0 references

Rainer H Böger

1

1 reference

6 December 2017

1 January 2003

1 reference

6 December 2017

1 reference

6 December 2017

8

1 reference

6 December 2017

3

1 reference

6 December 2017

149-151

1 reference

The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications

6 December 2017

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

A randomized trial of aggressive lipid reduction for improvement of myocardial ischemia, symptom status, and vascular function in patients with coronary artery disease not amenable to intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

When the endothelium cannot say ?NO? anymoreADMA, an endogenous inhibitor of NO synthase, promotes cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X03VM501ED

10.1191/1358863X03VM501ED

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference

PubMed ID

14989553